Result card

  • EFF1a: Are IVIG effective in slowing or avoiding progression from Mild Cognitive Impairment to Alzheimer’s disease when compared to placebo?
  • EFF1b: Are IVIG effective in improving biomarkers of progression from Mild Cognitive Impairment to Alzheimer’s disease when compared to placebo? Jump to
  • EFF1c: Are IVIG effective in improving imaging markers of progression from Mild Cognitive Impairment to Alzheimer’s disease when compared to placebo? Jump to
  • EFF1d: Are IVIG effective in slowing disease progression from mild-to-moderate to moderate-to-severe Alzheimer’s disease (measured with MMSE) when compared to placebo or acetyl cholinesterase inhibitors? Jump to
  • EFF1e: Are IVIG effective in improving biomarkers of progression in patients with mild-to-moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors? Jump to
  • EFF1f: Are IVIG effective in improving imaging markers of progression in patients with mild-to-moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors? Jump to
  • EFF1g: Are IVIG effective in improving biomarkers of progression in patients with moderate-to-severe Alzheimer’s disease when compared to placebo or memantine? Jump to
  • EFF1h: Are IVIG effective in improving imaging markers of progression in patients with moderate-to-severe Alzheimer’s disease when compared to placebo or memantine? Jump to
Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment
D0006
English
Guidance Resources

Are IVIG effective in slowing or avoiding progression from Mild Cognitive Impairment to Alzheimer’s disease when compared to placebo?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with MCI.

Critical
Completely
Vignatelli L et al. Result Card EFF1a In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in improving biomarkers of progression from Mild Cognitive Impairment to Alzheimer’s disease when compared to placebo?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with MCI.

Optional
Completely
Vignatelli L et al. Result Card EFF1b In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in improving imaging markers of progression from Mild Cognitive Impairment to Alzheimer’s disease when compared to placebo?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with MCI.

Optional
Completely
Vignatelli L et al. Result Card EFF1c In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in slowing disease progression from mild-to-moderate to moderate-to-severe Alzheimer’s disease (measured with MMSE) when compared to placebo or acetyl cholinesterase inhibitors?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with mild-to-moderate AD.

 

Critical
Completely
Vignatelli L et al. Result Card EFF1d In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in improving biomarkers of progression in patients with mild-to-moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with mild-to-moderate AD.

Optional
Completely
Vignatelli L et al. Result Card EFF1e In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in improving imaging markers of progression in patients with mild-to-moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with mild-to-moderate AD.

Optional
Completely
Vignatelli L et al. Result Card EFF1f In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in improving biomarkers of progression in patients with moderate-to-severe Alzheimer’s disease when compared to placebo or memantine?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with moderate-to-severe AD.

Optional
Completely
Vignatelli L et al. Result Card EFF1g In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in improving imaging markers of progression in patients with moderate-to-severe Alzheimer’s disease when compared to placebo or memantine?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence is available on effectiveness of IVIG for patients with moderate-to-severe AD.

Optional
Completely
Vignatelli L et al. Result Card EFF1h In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=267

References

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9.

Arai H, Ichimiya Y, Shibata N, Nakajima T, Sudoh S, Tokuda T, Sujaku T, Yokokawa S, Hoshii N, Noguchi H, Bille A. Safety and tolerability of immune globulin intravenous (human), 10% solution in Japanese subjects with mild to moderate Alzheimer's disease. Psychogeriatrics 2014;14:165-74.

Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011; 377:1019-31.

Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64:401-6.

Bischkopf J, Busse A, Angermeyer MC. Mild cognitive impairment--a review of prevalence, incidence and outcome according to current approaches. Acta Psychiatr Scand 2002; 106:403-14.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012;69:98-106.

Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry 2013; 203:255-64.

Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jäckel S, Wei X, Buerger K, Höft C, Hemmer B, Möller HJ, Farlow M, Oertel WH, Sommer N, Du Y. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002;52:253-6.

Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013;12:233-43.

Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, Bales K, Gao F, Moeller HJ, Oertel W, Farlow M, Paul S. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001 11;57:801-5.

EUnetHTA Joint Action WP5. HTA Core Model for Rapid Relative Effectiveness Assessment of Pharmaceuticals. 1 March 2013 – V3.0. Available at http://www.eunethta.eu/outputs/new-application-hta-core-model-hta-core-model-rapid-relative-effectiveness-assessment-pharma; last access February 19th 2014.

Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011a; 64:383-94.

Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, Norris SL, Williams JW Jr, Atkins D, Meerpohl J, Schünemann HJ. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol 2011b; 64:407-15

Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, Alonso-Coello P, Djulbegovic B, Atkins D, Falck-Ytter Y, Williams JW Jr, Meerpohl J, Norris SL, Akl EA, Schünemann HJ. GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol 2011c; 64:1277-82.

Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JW Jr, Murad MH, Sinclair D, Falck-Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J, Schünemann HJ. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol 2011d; 64:1283-93.

Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Glasziou P, Jaeschke R, Akl EA, Norris S, Vist G, Dahm P, Shukla VK, Higgins J, Falck-Ytter Y, Schünemann HJ; GRADE Working Group. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol 2011e; 64:1294-302.

Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Falck-Ytter Y, Jaeschke R, Vist G, Akl EA, Post PN, Norris S, Meerpohl J, Shukla VK, Nasser M, Schünemann HJ; GRADE Working Group. GRADE guidelines: 8. Rating the quality of evidence--indirectness. J Clin Epidemiol 2011f; 64: 1303-10.

Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, Atkins D, Kunz R, Brozek J, Montori V, Jaeschke R, Rind D, Dahm P, Meerpohl J, Vist G, Berliner E, Norris S, Falck-Ytter Y, Murad MH, Schünemann HJ; GRADE Working Group. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 2011g; 64:1311-6

Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, Brozek J, Norris S, Meerpohl J, Djulbegovic B, Alonso-Coello P, Post PN, Busse JW, Glasziou P, Christensen R, Schünemann HJ. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol 2013; 66:158-72.

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Chapter 5:  Defining the review question and developing criteria for including studies; last access February 19th 2014.

HTA Core Model Handbook Online, Version 1.5. Available at https://meka.thl.fi/htacore/ViewHandbook.aspx, access 8th October 2014.

HTA Core Model Application for Pharmaceuticals, 2.0. Available at https://meka.thl.fi/htacore/ViewApplication.aspx?id=14235, access 8th October 2014.

Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013 ;12:207-16.

Loeffler DA. Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation 2013 Jun 5;10:70.

McDade EM, Petersen RC. Mild cognitive impairment: Epidemiology, pathology, and clinical assessment. UpToDate® 2014; available from www.uptodate.com; accessed 2014 January 9th.

McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:263-9.

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6(6): e1000097. doi:10.1371/journal.pmed1000097

National Institute on Aging. Alzheimer’s disease - Unraveling the Mystery. U.S. Department of Health and Human Services NIH Publication Number: 08-3782; September 2011; available from www.nia.nih.gov/alzheimers, last access 29th January 2014.

National Institute for Health and Clinical Excellence (NICE). NICE technology appraisal guidance 217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of NICE technology appraisal guidance 111). 2011; available from www.nice.org.uk/guidance/TA217, accessed 2014 Jan 30th.

NCT00299988. Available at http://prsinfo.clinicaltrial.gov/ct2/show/NCT00299988?term=NCT00299988&rank=1; last access 16th December 2014.

NCT00818662. Available at http://prsinfo.clinicaltrial.gov/ct2/show/record/NCT00818662?term=NCT00818662&rank=1; last access 16th December 2014.

NCT01300728. Available http://prsinfo.clinicaltrial.gov/ct2/show/NCT01300728?term=NCT01300728&rank=1, last access 16th December 2014.

NCT01524887. Available at http://prsinfo.clinicaltrial.gov/ct2/results?term=NCT01524887&Search=Search, last access 16th December 2014.

NCT01561053. Available at http://prsinfo.clinicaltrial.gov/ct2/show/NCT01561053?term=NCT01561053&rank=1, last access 16th December 2014.

NCT01736579. Available at http://prsinfo.clinicaltrial.gov/ct2/results?term=NCT01736579&Search=Search, last access 16th December 2014.

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8.

Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009;30:1728-36.

Silvergleid AJ, Berger M. General principles in the use of immune globulin. 2013a UpToDate®; available from www.uptodate.com, last access 9th October 2013.

Weksler ME, Goodhardt M. Do age-associated changes in 'physiologic' autoantibodies contribute to infection, atherosclerosis, and Alzheimer's disease? Exp Gerontol. 2002;37:971-9.